KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$5.90 USD
-0.16 (-2.64%)
Updated Aug 28, 2024 01:57 PM ET
After-Market: $5.96 +0.06 (1.02%) 7:18 PM ET
2-Buy of 5 2
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
KALA BIO, Inc. [KALA]
Reports for Purchase
Showing records 301 - 320 ( 367 total )
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Q1; INVELTYS - U.S Launch On-track; Next: Dry Eye PDUFA August 15
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
ARVO 2019 Conference Highlights: Next-Generation Ophthalmology Therapeutics Emerge
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
1Q19 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Weekly Symphony Health Estimates for INVELTYS....
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
2018 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
Q4 FY18; INVELTYS Launch Off to a Good Start in Our View; Dry Eye Aug 15 PDUFA
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Medical - Biomedical and Genetics
KPI-121 Competitive Landscape Improves in Dry Eye Disease; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R